Ignite Creation Date:
2024-05-06 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06237257
Status:
RECRUITING
Last Update Posted:
2024-04-11
First Post:
2024-01-23
Brief Title:
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
Sponsor:
Shanghai Shengdi Pharmaceutical Co Ltd
Organization:
Shanghai Shengdi Pharmaceutical Co Ltd
Study Overview
Official Title:
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Primary purpose of this study is to evaluate the safety of SHR-1316 plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer
The second purpose of this study is to evaluate the efficacy and PK traits The exploratory study is to explore the biomarker immunogenicity and so on
The second purpose of this study is to evaluate the efficacy and PK traits The exploratory study is to explore the biomarker immunogenicity and so on
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None